BidaskClub lowered shares of Sangamo Therapeutics (NASDAQ:SGMO) from a strong-buy rating to a buy rating in a research report report published on Tuesday.
A number of other analysts also recently issued reports on the stock. Bank of America started coverage on shares of Sangamo Therapeutics in a report on Wednesday, June 20th. They set a buy rating and a $24.00 price objective for the company. Cowen restated a buy rating on shares of Sangamo Therapeutics in a report on Monday, July 23rd. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 14th. ValuEngine downgraded shares of Sangamo Therapeutics from a strong-buy rating to a buy rating in a report on Thursday, September 6th. Finally, Wedbush restated a hold rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Sangamo Therapeutics has a consensus rating of Buy and a consensus price target of $20.57.
Shares of SGMO stock traded up $0.26 on Tuesday, hitting $14.00. The stock had a trading volume of 1,691,988 shares, compared to its average volume of 2,282,169. The company has a market cap of $1.72 billion, a P/E ratio of -20.00 and a beta of 2.97. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 7.24. Sangamo Therapeutics has a 12-month low of $11.30 and a 12-month high of $27.50.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The firm had revenue of $21.42 million during the quarter, compared to analysts’ expectations of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The business’s revenue for the quarter was up 159.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. As a group, research analysts expect that Sangamo Therapeutics will post -0.69 earnings per share for the current fiscal year.
In other Sangamo Therapeutics news, Director H Stewart Parker bought 2,000 shares of the business’s stock in a transaction on Friday, September 7th. The stock was purchased at an average price of $13.52 per share, for a total transaction of $27,040.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Edward R. Conner sold 5,000 shares of the stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $13.45, for a total transaction of $67,250.00. The disclosure for this sale can be found here. Insiders have sold 30,000 shares of company stock valued at $434,950 in the last 90 days. 1.20% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its position in Sangamo Therapeutics by 42.2% during the second quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock worth $11,218,000 after purchasing an additional 234,346 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Sangamo Therapeutics by 14.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 565,601 shares of the biopharmaceutical company’s stock worth $8,032,000 after purchasing an additional 71,134 shares during the period. Platinum Investment Management Ltd. bought a new position in Sangamo Therapeutics during the second quarter worth about $751,000. Bain Capital Public Equity Management LLC bought a new position in Sangamo Therapeutics during the second quarter worth about $2,002,000. Finally, Cubist Systematic Strategies LLC boosted its position in Sangamo Therapeutics by 193.6% during the first quarter. Cubist Systematic Strategies LLC now owns 65,087 shares of the biopharmaceutical company’s stock worth $1,237,000 after purchasing an additional 42,917 shares during the period. Hedge funds and other institutional investors own 63.84% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Recommended Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.